



POSTER PRESENTATION

Open Access

# Recombinant Env proteins that bind the quaternary-specific, V1/V2-directed PGT antibodies

J Gorman<sup>1\*</sup>, J McLellan<sup>1</sup>, Y Yang<sup>1</sup>, T Zhou<sup>1</sup>, J Zhu<sup>1</sup>, S Bangaru<sup>2</sup>, N Bayless<sup>2</sup>, P Alff<sup>2</sup>, CP Marshall<sup>2</sup>, PD Kwong<sup>1</sup>

From AIDS Vaccine 2012

Boston, MA, USA. 9-12 September 2012

## Background

Antibodies PGT141-145 are broadly neutralizing and recognize a glycan-dependent epitope in the V1/V2 loop, similar to antibodies PG9 and PG16. Collectively, this class of antibodies binds preferentially to the functional viral spike. Although PG9, and to a lesser extent, PG16, bind monomeric gp120s and V1/V2 scaffolds, to date no recombinant env-derived proteins have been identified that bind to antibodies PGT141-145.

## Methods

As a first step toward obtaining structural information of the epitope recognized by PGT141-145, we have created and characterized novel gp140s and epitope scaffolds designed to present the V1/V2 conformation recognized by PGT141-145. To date, over 70 recombinant proteins have been expressed and tested for antibody binding.

## Results

We have identified one V1/V2-scaffold protein that binds to PGT142. The binding is dependent on the HIV-1 strain used in the scaffold. We have also produced trimeric, cleaved gp140 constructs and evaluated them for binding to PGT141-145.

## Conclusion

Proteins that accurately mimic V1/V2 conformations of the functional viral spike are crucial to obtaining structures of the PGT antibodies in complex with their epitopes, and may be ideal immunogens for eliciting broadly neutralizing, V1/V2-directed antibodies in a vaccine setting.

## Author details

<sup>1</sup>National Institutes of Health, Bethesda, MD, USA. <sup>2</sup>Avatar Biotechnologies, Brooklyn, NY, USA.

Published: 13 September 2012

doi:10.1186/1742-4690-9-S2-P84

Cite this article as: Gorman *et al.*: Recombinant Env proteins that bind the quaternary-specific, V1/V2-directed PGT antibodies. *Retrovirology* 2012 **9** (Suppl 2):P84.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



<sup>1</sup>National Institutes of Health, Bethesda, MD, USA  
Full list of author information is available at the end of the article